by John R. Fischer
, Senior Reporter | May 16, 2019
Bruker and the Champalimaud Foundation
are developing the first 18 Tesla
11 cm bore, preclinical ultra-high
field MR system
Bruker has teamed up with the Champalimaud Foundation, a biomedical research foundation in Portugal, to develop the first 18 Tesla 11 cm bore, preclinical ultra-high-field MR (UHF MR) system and its clinical research applications.
Announced at the Annual Meeting of the International Society for Magnetic Resonance in Medicine, the solution is expected to advance research endeavors at Champalimaud around translational cancer and neuroscience through the use of UHF MR and magnetic resonance spectroscopic imaging.
"We are very excited to explore the full potential of the 18T MR system, and to advance our understanding of biological mechanisms underlying healthy and diseased conditions,” Dr. Noam Shemesh, principal investigator at the Champalimaud Foundation, said in a statement. “We intend to harness the 18T ultra-high-field and enhanced sensitivity to facilitate investigations into microstructure and metabolism dynamics in the brain, as well as in cancer, highlighting MR as a tool for answering fundamental questions in biology, and not 'just' as a powerful diagnostic tool.”
For those who need to move fast and expand clinical capabilities -- and would love new equipment -- the uCT 550 Advance offers a new fully configured 80-slice CT in up to 2 weeks with routine maintenance and parts and Software Upgrades for Life™ included.
The aim behind using 18T MR is to improve clinical outcomes through the development of new spatially-resolved contrast mechanisms for elucidating biological function with MR and spectroscopic imaging, as well as enhance temporal resolution for retrieving additional information on brain dynamics.
The system is expected to advance in vivo research at the Champalimaud Foundation for cancer, metastasis, and pre-metastatic niches (PMNs) in multiple cancer models. It also will be implemented in the study of brain plasticity and activity in normal and neurodegenerative disease models.
"We are extremely pleased to partner with the Champalimaud Foundation to collaborate on unique, enabling research tools to advance scientific research in both neuroscience and oncology,” said Dr. Wulf-Ingo Jung, president of Bruker's preclinical imaging division, in a statement. “This exciting UHF MR partnership will be a demonstration of what can be achieved in collaboration with a leading medical research institution."
Development of the 18 Tesla MR scanner comes a year and half after the installation of Bruker’s 15.2 Tesla MR system
at The Weizmann Institute of Science in Israel, and months after energizing the world's first stable and homogeneous standard-bore Ascend 1.1 GHz NMR magnet
in late 2018.
The system is expected to be installed in late 2021 in the Foundation’s Neuroplasticity and Neural Activity laboratory.
Bruker did not respond for comment.